Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human epidermal growth factor + recombinant human basic fibroblast growth factor
- Development stage
- Preclinical
- Lead developer
- Uni-Bio Science Group
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
EGF/bFGF is a combination biologic therapy under development by Uni-Bio Science Group. It consists of recombinant human epidermal growth factor (rhEGF) and recombinant human basic fibroblast growth factor (rhbFGF) formulated within a hydrogel delivery system. The therapy is designed to synergistically promote wound healing by activating the EGF receptor (EGFR) and FGF receptor (FGFR) pathways, which stimulate cell proliferation, migration, and angiogenesis. Targeted indications include burns, refractory wounds, diabetic foot ulcers, and skin recovery following laser procedures. The hydrogel formulation provides a moist environment and potentially protects the growth factors from degradation, enhancing their therapeutic efficacy in complex wound environments.
- Other names
- EGF + bFGF hydrogelUni-Bio EGF/bFGF
02
Targets
EGFR (Epidermal growth factor receptor)FGFR (FGFR family)
Beyond the preview
Go deeper on recombinant human epidermal growth factor + recombinant human basic fibroblast growth factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human epidermal growth factor + recombinant human basic fibroblast growth factor.